Wire · operational-macro
US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The US FDA declined to approve Capricor Therapeutics' experimental cell therapy deramiocel for Duchenne muscular dystrophy due to serious data integrity issues in the clinical trial, causing the company's shares to plunge 77%.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Nov 2026 and 21 Nov 2026.
◆ ◆ The Wire takeaway
You must brace for tighter scrutiny on clinical trial data reliability as the FDA rejects treatments with questionable data. This rejection opens the field for rivals who can deliver robust evidence for Duchenne therapies.
◆ Coverage
2 sources · first reported 12 Nov 2026 · latest 21 Nov 2026
◆ Related on Wire
◆ Topics